Clinical data | |
---|---|
Trade names | Farydak |
Other names | LBH-589 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 21%[2] |
Protein binding | 90%[2] |
Metabolism | CYP3A (40%), CYP2D6, CYP2C19[2] |
Elimination half-life | 37 hours[2] |
Excretion | Fecal (44–77%), renal (29–51%)[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.230.582 |
Chemical and physical data | |
Formula | C21H23N3O2 |
Molar mass | 349.434 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma.[2][3] It is a hydroxamic acid[4] and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).[5]
Panobinostat was approved for medical use in the United States in February 2015,[2][6][7] and in the European Union in August 2015.[3][8] However, in March 2022, it was withdrawn in the United States.[9][10]
Revill2007
was invoked but never defined (see the help page).